XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
← catalyst calendarSponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
72actual
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-10 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-Resistant Prostate Cancer
Interventions
- Combination product: vudalimab + carboplatin + cabazitaxel
- Combination product: vudalimab + olaparib
- Biological: vudalimab monotherapy
- Combination product: vudalimab + docetaxel
- Combination product: vudalimab + cabazitaxel or docetaxel
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (safety and tolerability of vudalimab)
measured 8 weeks
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed